$T2バイオシステムズ(TTOO.US)$In a recent filing with the United States Securities and Exchange Commission, Nathan D. Hukill, along with associated entities including CR Group L.P. and various CRG Partners funds, reported a significant change in their beneficial ownership of T2 Biosystems, Inc. The group now collectively owns 8,853,173 shares, representing approximately 65.4% of the company's issued and outstanding common stock. This change in ownership is a result of the cancellation of outstand...
$T2バイオシステムズ(TTOO.US)$Reuters· 1 min ago T2 Biosystems Inc: Signed a Non-Binding Letter of Intent to Enter Into a Strategic Partnership With Eco Laboratory
$T2バイオシステムズ(TTOO.US)$ NEWS T2 Biosystems Announces First Quarter 2024 Financial Results T2 Biosystems, a leader in sepsis detection, announced Q1 2024 financial results, showing 25% growth in sepsis product revenue. They converted $30M debt into equity, signed key agreements, and focused on product development. 25% growth in sepsis product revenue in Q1 2024 Reduced debt by 80% compared to the prior year Signed key agreements to strengthen the balance sheet Received FDA clearances for product...
$T2バイオシステムズ(TTOO.US)$ NEWS T2 Biosystems Announces Commercial Expansion Through Middle East Distributor T2 Biosystems, Inc. (NASDAQ:TTOO) has announced a territory exclusive distribution agreement in Qatar to sell T2Dx® Instruments, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel through a new distributor. The agreement expands the company's commercialization in the Middle East, catering to Qatar's strong focus on sepsis care. The move aims to enable rapid detection o...
T2バイオシステムズに関するコメント
T2 Biosystems Inc: Signed a Non-Binding Letter of Intent to Enter Into a Strategic Partnership With Eco Laboratory
T2 Biosystems Inc: Announced Execution of Territory Exclusive Distribution Agreement in Qatar
NEWS
T2 Biosystems Announces First Quarter 2024 Financial Results
T2 Biosystems, a leader in sepsis detection, announced Q1 2024 financial results, showing 25% growth in sepsis product revenue. They converted $30M debt into equity, signed key agreements, and focused on product development.
25% growth in sepsis product revenue in Q1 2024
Reduced debt by 80% compared to the prior year
Signed key agreements to strengthen the balance sheet
Received FDA clearances for product...
NEWS
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor
T2 Biosystems, Inc. (NASDAQ:TTOO) has announced a territory exclusive distribution agreement in Qatar to sell T2Dx® Instruments, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel through a new distributor. The agreement expands the company's commercialization in the Middle East, catering to Qatar's strong focus on sepsis care. The move aims to enable rapid detection o...
まだコメントはありません